Sign In
Buy MRNA
$59.81
+0.640 (+1.08%)
At Close: Aug 10, 2026
Moderna set for uneventful Q2 report ahead of key data readouts, says Jefferies
09:35am, Tuesday, 14'th Jul 2026
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) is expected to report second quarter results on July 31, with investors focused on the impact of seasonal COVID-19...
Moderna (MRNA) Registers a Bigger Fall Than the Market: Important Facts to Note
06:51pm, Monday, 13'th Jul 2026
Moderna (MRNA) reached $66.98 at the closing of the latest trading day, reflecting a -1.89% change compared to its last close.
Arbutus Biopharma: Moderna Validates My IP Bull Case
08:00am, Monday, 13'th Jul 2026
Arbutus Biopharma is now much better capitalized after Moderna validated the value of its LNP patents. As for ABUS' in-house assets, I think Imdusiran has shown durable viral control. The main caveat
Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout
12:04pm, Friday, 10'th Jul 2026
Biotech is the story at midday Friday, and it's not a pretty one for shareholders who chased the sector's monster 2026 run.
Moderna wins EU contract for RSV vaccine supply
07:17am, Thursday, 09'th Jul 2026
Moderna said on Thursday it has secured a European Commission contract to supply its respiratory syncytial virus vaccine to six countries in the region.
Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
07:00am, Thursday, 09'th Jul 2026
CAMBRIDGE, MA / ACCESS Newswire / July 9, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, July 31, 2026 to report it
Moderna Appoints Michael McDonnell to Board of Directors
07:00am, Wednesday, 08'th Jul 2026
Former Biogen Chief Financial Officer brings more than 35 years of financial leadership and public company experience CAMBRIDGE, MA / ACCESS Newswire / July 8, 2026 / Moderna, Inc. (NASDAQ:MRNA) today
Moderna Stock Is Soaring. Is It Too Late to Buy?
05:15am, Tuesday, 07'th Jul 2026
Moderna is no longer just a COVID-19 vaccine company. A growing pipeline could fuel long-term revenue growth.
Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know
06:50pm, Monday, 06'th Jul 2026
Moderna (MRNA) closed at $81.76 in the latest trading session, marking a +2.51% move from the prior day.
These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even More
06:10pm, Monday, 06'th Jul 2026
Each of these biotech players has reached an important turning point. Recent drug approvals could supercharge the performance of one in particular.
2 More Stocks to Buy for the AI Convergence
12:00pm, Sunday, 05'th Jul 2026
Tom Yeung here with your Sunday Digest . In the days following its IPO, Space Exploration Technologies Corp. ( SPCX ) surged 25%, rewarding early investors and turning its owner, Elon Musk, into a tri
Moderna Is Up More Than 70% in a Month After a 9-0 FDA Vote. Wall Street's Average Price Target Says It Should Fall 44%.
01:07pm, Friday, 03'rd Jul 2026
An FDA advisory panel voted 9-0 that Moderna's mRNA flu vaccine's benefits outweigh its risks. A final approval decision is expected by Aug. 5.
MRNA Stock on the Move: What Sparked the 33.5% Jump in the Past Week?
12:35pm, Friday, 03'rd Jul 2026
Moderna surges 33.5% after the company outlines plans to expand its mRNA platform beyond vaccines into oncology, autoimmune diseases and cell therapies.
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?
11:14am, Friday, 03'rd Jul 2026
Moderna is evolving from a COVID-19 vaccine specialist into a multi-product firm with major oncology and rare disease partnerships. Recursion Pharmaceuticals is leveraging artificial intelligence and
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?
08:37am, Friday, 03'rd Jul 2026
Arcutis doubled revenue last year while Vertex delivered strong profits and cash flow. Explore how each company stacks up on growth, risk, and value.
